Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 268

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

Open access
Hodson, Elisabeth M, Ladhani, Maleeka, Webster, Angela C, Strippoli, Giovanni FM, Craig, Jonathan C·2013·Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: The risk of cytomegalovirus (CMV) infection in solid organ transplant recipients has resulted in the frequent use of prophylaxis with the aim of preventing the clinical syndrome associated with CMV infection. This is an update of a review first published in 2005 and updated in 2008. OBJECTIVES: To determine the benefits and harms of antiviral medications to prevent CMV disease and all-cause mortality in solid organ transplant recipients. SEARCH METHODS: We searched MEDLINE, EMBASE and the Cochrane Central Registry of Controlled Trials (CENTRAL) in The Cochrane Library to February 2004 for the first version of this review. The Cochrane Renal Group's specialised register was searched to February 2007 and to July 2011 for the first and current updates of the review without language restriction. SELECTION CRITERIA: We included randomised controlled trials (RCTs) and quasi-RCTs comparing antiviral medications with placebo or no treatment, comparing different antiviral medications and comparing different regimens of the same antiviral medications in recipients of any solid organ transplant. Studies examining pre-emptive therapy were excluded. DATA COLLECTION AND ANALYSIS: Two authors independently assessed study eligibility, risk of bias and extracted data. Results were reported as risk ratios (RR) or risk differences (RD) with 95% confidence intervals (CI) for dichotomous outcomes and by mean difference (MD) with 95% CI for continuous outcomes. Statistical analyses were performed using the random-effects model. Subgroup analysis and univariate meta-regression were performed using restricted maximum-likelihood to estimate the between study variance. Multivariate meta-regression was performed to investigate whether the results were altered after allowing for differences in drugs used, organ transplanted, and recipient CMV serostatus at the time of transplantation. MAIN RESULTS: We identified 37 studies (4342 participants). Risk of bias attributes were poorly performed or reported with low risk of bias reported for sequence generation, allocation concealment, blinding and selective outcome reporting in 25% or fewer studies.Prophylaxis with aciclovir, ganciclovir or valaciclovir compared with placebo or no treatment significantly reduced the risk for CMV disease (19 studies; RR 0.42, 95% CI 0.34 to 0.52), CMV infection (17 studies; RR 0.61, 95% CI 0.48 to 0.77), and all-cause mortality (17 studies; RR 0.63, 95% CI 0.43 to 0.92) primarily due to reduced mortality from CMV disease (7 studies; RR 0.26, 95% CI 0.08 to 0.78). Prophylaxis reduced the risk of herpes simplex and herpes zoster disease, bacterial and protozoal infections but not fungal infection, acute rejection or graft loss.Meta-regression showed no significant difference in the relative benefit of treatment (risk of CMV disease or all-cause mortality) by organ transplanted or CMV serostatus; no conclusions were possible for CMV negative recipients of negative organs.Neurological dysfunction was more common with ganciclovir and valaciclovir compared with placebo/no treatment. In direct comparison studies, ganciclovir was more effective than aciclovir in preventing CMV disease (7 studies; RR 0.37, 95% CI 0.23 to 0.60) and leucopenia was more common with aciclovir. Valganciclovir and IV ganciclovir were as effective as oral ganciclovir. The efficacy and adverse effects of valganciclovir/ganciclovir did not differ from valaciclovir in three small studies. Extended duration prophylaxis significantly reduced the risk of CMV disease compared with three months therapy (2 studies; RR 0.20, 95% CI 0.12 to 0.35). Leucopenia was more common with extended duration prophylaxis but severe treatment associated adverse effects did not differ between extended and three month durations of treatment. AUTHORS' CONCLUSIONS: Prophylaxis with antiviral medications reduces CMV disease and CMV-associated mortality in solid organ transplant recipients. These data suggest that antiviral prophylaxis should be used routinely in CMV positive recipients and in CMV negative recipients of CMV positive organ transplants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003774.pub4

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Research works printed but not linked: 129

  1. Reischig, 2010, Lymphocyte function during valacyclovir and valganciclovir cytomegalovirus prophylaxis in renal transplant recipients [abstract], American Journal of Transplantation, 10, 143
  2. Reischig, 2011, Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients, Antiviral Therapy, 16, 1227, 10.3851/IMP1879 · doi:10.3851/imp1879
  3. Ahsan, 1996, Oral ganciclovir (CytoveneR) effectively prevents cytomegalovirus (CMV) infection in renal transplant patients [abstract], Journal of the American Society of Nephrology, 7, 1929
  4. Ahsan, 1997, Oral ganciclovir is effective in preventing CMV infection in renal transplant recipients [abstract], Nephrology, 3, S70
  5. Balfour, 1991, Prevention of cytomegalovirus disease in renal allograft recipients, Scandinavian Journal of Infectious Diseases - Supplement, 80, 88
  6. Balfour, 1989, A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts, New England Journal of Medicine, 320, 1381, 10.1056/NEJM198905253202105 · doi:10.1056/nejm198905253202105
  7. Balfour, 1982, Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution, American Journal of Medicine, 73, 241, 10.1016/0002-9343(82)90099-7 · doi:10.1016/0002-9343(82)90099-7
  8. Balfour, 1991, Prevention of cytomegalovirus disease with oral acyclovir, Transplantation Proceedings, 23, 17
  9. Fletcher, 1991, Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients, Antimicrobial Agents & Chemotherapy, 35, 938, 10.1128/AAC.35.5.938 · doi:10.1128/aac.35.5.938
  10. Barkholt, 1999, High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients, Transplant Infectious Disease, 1, 89, 10.1034/j.1399-3062.1999.010202.x · doi:10.1034/j.1399-3062.1999.010202.x
  11. Brennan, 1997, Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients, Transplantation, 64, 1843, 10.1097/00007890-199712270-00036 · doi:10.1097/00007890-199712270-00036
  12. Brennan, 1997, Prophylactic oral ganciclovir prevents cytomegalovirus disease in renal transplant recipients [abstract], Nephrology, 3, S197
  13. Brennan, 2000, The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir, Journal of Infectious Diseases, 181, 1557, 10.1086/315477 · doi:10.1086/315477
  14. Singer, 1996, Prophylactic oral ganciclovir prevents cytomegalovirus disease in high-risk renal transplant recipients. [abstract], Journal of the American Society of Nephrology, 7, 1941
  15. Cohen, 1993, Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults, Journal of Medical Virology, 40, 5, 10.1002/jmv.1890400103 · doi:10.1002/jmv.1890400103
  16. Flechner, 1998, A randomized prospective trial of oral acyclovir vs oral ganciclovir for CMV prophylaxis in high risk kidney transplant recipients [abstract], Transplantation, 65, S187, 10.1097/00007890-199806270-00758 · doi:10.1097/00007890-199806270-00758
  17. Saliba, 1997, A randomized double blind versus placebo multicenter study of efficacy and tolerance of oral ganciclovir in the prevention of cytomegalovirus disease in hepatic transplanted patients, Gastroenterologie Clinique et Biologique, 21, A157
  18. Gavalda, 1997, Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients, Transplant International, 10, 462, 10.1111/j.1432-2277.1997.tb00725.x · doi:10.1111/j.1432-2277.1997.tb00725.x
  19. Green, 1997, Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein- Barr virus disease after liver transplantation in children, Clinical Infectious Diseases, 25, 1344, 10.1086/516139 · doi:10.1086/516139
  20. Green, 1994, Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis, Transplantation Proceedings, 26, 173
  21. Hertz, 1998, Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation, Journal of Heart & Lung Transplantation, 17, 913
  22. Blumberg, 2010, Cost-effectiveness model to evaluate 200-day vs 100-day valganciclovir (Valcyte®) prophylaxis to reduce CMV disease incidence post-transplant [abstract], American Journal of Transplantation, 10, 126
  23. Chou, 2010, Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis, Transplantation, 90, 1409, 10.1097/TP.0b013e3181fdd9d2 · doi:10.1097/tp.0b013e3181fdd9d2
  24. Elston, 2010, The IMPACT Study: genotypic analysis of cytomegalovirus UL54 and UL97 genes derived from patients receiving 100 or 200 days of valganciclovir (Valcyte®) prophylaxis [abstract], American Journal of Transplantation, 10, 208
  25. Humar, 2011, Response to questions regarding the design and results of the IMPACT trial, American Journal of Transplantation, 11, 177, 10.1111/j.1600-6143.2010.03370.x · doi:10.1111/j.1600-6143.2010.03370.x
  26. Humar, 2010, Long term results of the IMPACT study: 200 vs 100 days of valganciclovir prophylaxis in kidney transplant recipients [abstract], American Journal of Transplantation, 10, 143
  27. Humar, 2009, The Impact Study: Valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease [abstract], American Journal of Transplantation, 9, 248
  28. Humar, 2010, Extended valganciclovir prophylaxis in D/R kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT Study, Transplantation, 90, 1427, 10.1097/TP.0b013e3181ff1493 · doi:10.1097/tp.0b013e3181ff1493
  29. Welker, 2010, Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days, Transplantation, 90, 1414, 10.1097/TP.0b013e3182000042 · doi:10.1097/tp.0b013e3182000042
  30. Kletzmayr, 1996, Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients, Journal of the American Society of Nephrology, 7, 325, 10.1681/ASN.V72325 · doi:10.1681/asn.v72325
  31. Leray, 1995, Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients, Transplantation Proceedings, 27, 2448
  32. Legendre, 2000, Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation, Transplantation, 70, 1463, 10.1097/00007890-200011270-00012 · doi:10.1097/00007890-200011270-00012
  33. Lowance, 1998, Valaciclovir reduces the incidence of cytomegalovirus disease and acute graft rejection in CMV-seronegative recipients of a seropositive cadaveric renal allograft [abstract], Transplantation, 65, S18, 10.1097/00007890-199806270-00084 · doi:10.1097/00007890-199806270-00084
  34. Wagner JA Ross H Hunt S Gamberg P Valantine H Merigan TC Stinson EB Prophylactic ganciclovir treatment reduces cytomegalovirus and fungal infections in orthotopic heart transplant recipients ASTP 1995 Annual Meeting 1995 · doi:10.1097/00007890-199560120-00018
  35. Wagner, 1995, Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation, Transplantation, 60, 1473, 10.1097/00007890-199560120-00018 · doi:10.1097/00007890-199560120-00018
  36. Nafar, 2005, A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients, Transplantation Proceedings, 37, 3053, 10.1016/j.transproceed.2005.08.007 · doi:10.1016/j.transproceed.2005.08.007
  37. Nakazato, 1993, Viral prophylaxis in hepatic transplantation: Preliminary report of a randomized trial of acyclovir and gancyclovir, Transplantation Proceedings, 25, 1935
  38. Pavlopoulou, 2005, A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients, Clinical Microbiology & Infection, 11, 736, 10.1111/j.1469-0691.2005.01215.x · doi:10.1111/j.1469-0691.2005.01215.x
  39. Boivin, 2004, Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients, Journal of Infectious Diseases, 189, 1615, 10.1086/382753 · doi:10.1086/382753
  40. Freeman, 2003, Risk factors for cytomegalovirus (CMV) disease: results from a multicenter randomized trial of valganciclovir (VGC) [abstract], American Journal of Transplantation, 3, 391
  41. Humar, 2005, Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients, American Journal of Transplantation, 5, 1065, 10.1111/j.1600-6143.2005.00797.x · doi:10.1111/j.1600-6143.2005.00797.x
  42. Pescovitz, 2003, Valganciclovir for prevention of CMV disease: 12 month follow up of a randomized trial of 364 D+/R- transplant recipients [abstract], American Journal of Transplantation, 3, 299
  43. Wiltshire, 2005, Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients, Clinical Pharmacokinetics, 44, 495, 10.2165/00003088-200544050-00003 · doi:10.2165/00003088-200544050-00003
  44. Wiltshire, 2005, Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients, Transplantation, 79, 1477, 10.1097/01.TP.0000164512.99703.AD · doi:10.1097/01.tp.0000164512.99703.ad
  45. Pouteil-Noble, 1996, Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: A randomized, controlled trial, Transplantation Proceedings, 28, 2811
  46. Reischig T Bouda M Opatrny KJ Treska V Jindra P Svecova M Oral ganciclovir versus valacyclovir for prophylaxis of cytomegalovirus disease in renal transplant recipients [abstract] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002 · doi:10.1007/s00147-002-0475-0
  47. Reischig, 2004, Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection: a randomized comparison with oral ganciclovir and deferred therapy. [abstract], Transplantation, 78, 483, 10.1097/00007890-200407271-01301 · doi:10.1097/00007890-200407271-01301
  48. Reischig, 2005, Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection, Transplantation, 79, 317, 10.1097/01.TP.0000150024.01672.CA · doi:10.1097/01.tp.0000150024.01672.ca
  49. Reischig, 2004, Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection: a randomized comparison of oral ganciclovir and valacyclovir [abstract], American Journal of Transplantation, 4, 493
  50. Reischig, 2006, The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection, Journal of Clinical Virology, 36, 146, 10.1016/j.jcv.2006.01.015 · doi:10.1016/j.jcv.2006.01.015
  51. Reischig, 2005, The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft infection [abstract], American Journal of Transplantation, 5, 382
  52. Reischig, 2005, Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients, Kidney & Blood Pressure Research, 28, 218, 10.1159/000087129 · doi:10.1159/000087129
  53. Reischig, 2002, A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation, Transplant International, 15, 615, 10.1111/j.1432-2277.2002.tb00120.x · doi:10.1111/j.1432-2277.2002.tb00120.x
  54. Rondeau, 1993, Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients, Nephrology Dialysis Transplantation, 8, 858
  55. Rondeau, 1992, Prophylaxis of CMV disease by ganciclovir (DHPG) in seronegative recipients of renal allograft from seropositive donors, Transplant International, 5, S30, 10.1111/tri.1992.5.s1.30 · doi:10.1111/tri.1992.5.s1.30
  56. Saliba, 1993, Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients, Transplantation Proceedings, 25, 1444
  57. Winston, 2003, Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients, Transplantation, 75, 229, 10.1097/01.TP.0000040601.60276.96 · doi:10.1097/01.tp.0000040601.60276.96
  58. Winston, 2004, Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors, Transplantation, 77, 305, 10.1097/01.TP.0000093463.86584.AC · doi:10.1097/01.tp.0000093463.86584.ac
  59. Ahsan, 1998, Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant 'CMV at risk' recipients: A controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid), Transplantation Proceedings, 30, 1383, 10.1016/S0041-1345(98)00283-8 · doi:10.1016/s0041-1345(98)00283-8
  60. Arbo, 2000, Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis, Clinical Transplantation, 14, 19, 10.1034/j.1399-0012.2000.140105.x · doi:10.1034/j.1399-0012.2000.140105.x
  61. Brennan, 1997, Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients, Transplantation Proceedings, 29, 809, 10.1016/S0041-1345(96)00143-1 · doi:10.1016/s0041-1345(96)00143-1
  62. Brennan, 2000, The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir, Journal of Infectious Diseases, 181, 1557, 10.1086/315477 · doi:10.1086/315477
  63. Dickinson, 1996, Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients, Annals of Pharmacotherapy, 30, 1452, 10.1177/106002809603001215 · doi:10.1177/106002809603001215
  64. Fehir, 1989, Immune globulin (GAMMAGARD) prophylaxis of CMV infections in patients undergoing organ transplantation and allogeneic bone marrow transplantation, Transplantation Proceedings, 21, 3107
  65. Ferreira A Felipe CR Motegi SA Hosaka BA Tamura MK Kamura LA Relationship between immunosuppression and subsequent development of CMV disease [abstract] 3rd International Congress on Immunosuppression; 2004 Dec 8-11; San Diego, (CA) 2004 · doi:10.1097/00007890-200407271-00870
  66. Gerna, 2008, Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation, Transplantation, 86, 163, 10.1097/TP.0b013e31817889e4 · doi:10.1097/tp.0b013e31817889e4
  67. Greger, 1988, Are the risk of viral infections increased in kidney transplant patients receiving triple-drug therapy?, Transplantation Proceedings, 20, 466
  68. Griffiths, 1997, Prophylaxis against CMV infection in transplant patients, Journal of Antimicrobial Chemotherapy, 39, 299, 10.1093/jac/39.3.299 · doi:10.1093/jac/39.3.299
  69. Grundmann, 1986, The value of a prophylactic CMV-IgG-treatment in renal transplant recipients [abstract], Nephrology Dialysis Transplantation, 1, 144
  70. Hecht, 1988, Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia, Journal of Infectious Diseases, 157, 187, 10.1093/infdis/157.1.187 · doi:10.1093/infdis/157.1.187
  71. Jung, 2001, Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation, Transplantation Proceedings, 33, 3621, 10.1016/S0041-1345(01)02558-1 · doi:10.1016/s0041-1345(01)02558-1
  72. Jurim, 1996, Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection, Liver Transplantation & Surgery, 2, 370, 10.1002/lt.500020507 · doi:10.1002/lt.500020507
  73. Brennan, 2004, Preemptive vs prophylactic valganciclovir for CMV in renal transplantation: early results from a randomized, prospective trial [abstract no: SA-FC009], Journal of the American Society of Nephrology, 15, 23A
  74. Khoury, 2006, Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients, American Journal of Transplantation, 6, 2134, 10.1111/j.1600-6143.2006.01413.x · doi:10.1111/j.1600-6143.2006.01413.x
  75. Spinner, 2010, Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes, Transplantation, 90, 412, 10.1097/TP.0b013e3181e81afc · doi:10.1097/tp.0b013e3181e81afc
  76. Kim, 2000, The economic impact of cytomegalovirus infection after liver transplantation, Transplantation, 69, 357, 10.1097/00007890-200002150-00008 · doi:10.1097/00007890-200002150-00008
  77. Kletzmayr, 2000, Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients, Transplantation, 70, 1174, 10.1097/00007890-200010270-00008 · doi:10.1097/00007890-200010270-00008
  78. Kliem, 2008, Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial, American Journal of Transplantation, 8, 975, 10.1111/j.1600-6143.2007.02133.x · doi:10.1111/j.1600-6143.2007.02133.x
  79. Radermacher, 2006, Influence of prophylactic compared with early ganciclovir treatment on graft survival in renal allograft recipients [abstract], Journal of the American Society of Nephrology, 17, 111A
  80. Koetz, 2001, Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective double-blind, placebo-controlled study, Transplantation, 72, 1325, 10.1097/00007890-200110150-00025 · doi:10.1097/00007890-200110150-00025
  81. Kuypers, 1999, Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem, Nephrology Dialysis Transplantation, 14, 2304, 10.1093/ndt/14.10.2304 · doi:10.1093/ndt/14.10.2304
  82. Laske, 1991, Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation, Transplantation Proceedings, 23, 1170
  83. Laske, 1992, The prevention of cytomegalus infection after heart transplantation, Helvetica Chirurgica Acta, 58, 527
  84. Luan, 2009, Economic analysis of extended cytomegalovirus prophylaxis in high risk kidney transplant patients [abstract], American Journal of Transplantation, 9, 250
  85. MacDonald, 1991, Cytomegalovirus disease prophylaxis in seronegative recipients of kidneys from seropositive donors by combination of cytomegalovirus-hyperimmune globulin and low-dose acyclovir, Transplantation Proceedings, 23, 1355
  86. Marker, 1980, A trial of vidarabine for cytomegalovirus infection in renal transplant patients, Archives of Internal Medicine, 140, 1441, 10.1001/archinte.1980.00330220027012 · doi:10.1001/archinte.1980.00330220027012
  87. Martin, 1993, Antiviral prophylaxis for CMV infection in liver transplantation, Transplantation Proceedings, 25, 10
  88. Martin, 1994, Combination antiviral strategies in managing cytomegalovirus infection, Transplantation Proceedings, 26, 28
  89. Martin, 1995, Prophylactic cytomegalovirus management strategies, Transplantation Proceedings, 27, 23
  90. Moreno, 1999, Open clinical trial with oral acyclovir for the prophylaxis of disease by Cytomegalovirus in low risk liver transplant recipients, Enfermedades Infecciosas y Microbiologia Clinica, 17, 382
  91. Murray, 1997, Cost comparison of two approaches to the management of CMV infection in renal transplant recipients [abstract], Journal of the American Society of Nephrology, 8, 695A
  92. Pescovitz, 2009, A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients, American Journal of Transplantation, 9, 2324, 10.1111/j.1600-6143.2009.02768.x · doi:10.1111/j.1600-6143.2009.02768.x
  93. Pouteil-Noble, 1991, Influence of HLA compatibility on cytomegalovirus infection in kidney transplantation, Presse Medicale, 20, 2022
  94. Quieroga, 2003, A prospective, randomized controlled trial comparing oral ganciclovir with weekly monitored CMV-antigenemia in renal transplant patients with a high-risk for CMV infection [abstract], American Journal of Transplantation, 3, 511
  95. Rayes, 2001, Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation, Transplantation, 72, 881, 10.1097/00007890-200109150-00024 · doi:10.1097/00007890-200109150-00024
  96. Reischig, 2007, Valacyclovir prophylaxis for cytomegalovirus is associated with reduced risk of acute renal allograft rejection compared to preemptive valganciclovir therapy [abstract], Transplant International, 20, 185
  97. Reischig, 2010, Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients, Antiviral Therapy, 15, 23, 10.3851/IMP1485 · doi:10.3851/imp1485
  98. Reischig, 2008, Preemptive valganciclovir therapy is not associated with increase in cytomegalovirus (CMV) DNA in renal allograft biopsy specimens compared with valacyclovir prophylaxis [abstract], Transplantation, 86, 131, 10.1097/01.tp.0000332482.73775.a2 · doi:10.1097/01.tp.0000332482.73775.a2
  99. Reischig, 2010, Cytomegalovirus infection in the graft: Results of a randomised study comparing valacyclovir prophylaxis and preemptive treatment after renal transplantation [abstract], Kidney & Blood Pressure Research, 33, 324
  100. Sagedal, 2003, Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study, Nephrology Dialysis Transplantation, 18, 1899, 10.1093/ndt/gfg302 · doi:10.1093/ndt/gfg302
  101. Said, 2007, Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients, Transplantation Proceedings, 39, 997, 10.1016/j.transproceed.2007.03.046 · doi:10.1016/j.transproceed.2007.03.046
  102. Schnitzler, 2000, A 3-year follow-up of pre-emptive vs deferred treatment of cytomegalovirus disease in renal transplantation, Clinical Drug Investigation, 19, 367, 10.2165/00044011-200019050-00007 · doi:10.2165/00044011-200019050-00007
  103. Sing, 1994, High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients, Annals of Internal Medicine, 120, 375, 10.7326/0003-4819-120-5-199403010-00004 · doi:10.7326/0003-4819-120-5-199403010-00004
  104. Singh, 1995, Efficacy of cytomegalovirus prophylaxis in renal retransplantation, Transplantation Proceedings, 27, 964
  105. Singh, 2000, Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus iv ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients, Transplantation, 70, 717, 10.1097/00007890-200009150-00002 · doi:10.1097/00007890-200009150-00002
  106. Singh, 1998, CMV antigenemia directed preemptive prophylaxis with oral ganciclovir for the prevention of CMV disease in liver transplant recipients: a prospective, randomised, controlled trial. [abstract], Transplantation, 65, S113, 10.1097/00007890-199806270-00461 · doi:10.1097/00007890-199806270-00461
  107. Snydman, 1991, Cytomegalovirus infections in the immunocompromised transplant patient. Prevention of cytomegalovirus disease with intravenous immune globulin, Transplantation Proceedings, 23, 20
  108. Snydman, 1991, Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials, Transplantation Proceedings, 23, 1357
  109. Snydman, 1994, A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group, Transplantation Proceedings, 26, 23
  110. Stratta, 1992, A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy, Archives of Surgery, 127, 55, 10.1001/archsurg.1992.01420010065009 · doi:10.1001/archsurg.1992.01420010065009
  111. Valantine, 1995, Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: Evidence for a beneficial effect of hyperimmune globulin, Transplantation Proceedings, 27, 49
  112. Asberg, 2010, Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients, American Journal of Transplantation, 10, 1881, 10.1111/j.1600-6143.2010.03114.x · doi:10.1111/j.1600-6143.2010.03114.x
  113. Asberg, 2008, Oral valganciclovir and intravenous ganciclovir results in comparable long-term outcomes in transplant recipients with CMV disease: the VICTOR study [abstract], Transplantation, 86, 222, 10.1097/01.tp.0000332158.73633.ff · doi:10.1097/01.tp.0000332158.73633.ff
  114. Boivin, 2009, Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir, Antiviral Therapy, 14, 697, 10.1177/135965350901400512 · doi:10.1177/135965350901400512
  115. Manual, 2008, A prospective study of viral genetic polymorphisms in CMV glycoprotein B and their association with clinical and virologic outcomes in patients with CMV disease: results from the VICTOR Study [abstract], Transplantation, 86, 221, 10.1097/01.tp.0000332156.88880.c6 · doi:10.1097/01.tp.0000332156.88880.c6
  116. Manuel, 2009, Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease, Clinical Infectious Diseases, 49, 1160, 10.1086/605633 · doi:10.1086/605633
  117. Pescovitz, 2008, Management of post transplant CMV disease: lessons learned from the VICTOR trial [abstract], American Journal of Transplantation, 8, 183
  118. Yang, 1996, Indication of ganciclovir treatment during early cytomegalovirus (cmv) viremia in CMV seropositive recipients. a longitudinal study of CMV pp65 antigenemia (Ag) assay [abstract], Journal of the American Society of Nephrology, 7, 1928
  119. Yang, 1998, Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients, American Journal of Nephrology, 18, 373, 10.1159/000013379 · doi:10.1159/000013379
  120. Yang, 1999, A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients, Transplantation Proceedings, 31, 1125, 10.1016/S0041-1345(98)01930-7 · doi:10.1016/s0041-1345(98)01930-7
  121. Baliga, 2004, A nationwide survey of cytomegalovirus prophylaxis and treatment in the transplant community [abstract], American Journal of Transplantation, 4, 495
  122. Camacho-Gonzalez, 2011, 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience, Transplantation, 91, 245-50, 10.1097/TP.0b013e3181ffffd3 · doi:10.1097/tp.0b013e3181ffffd3
  123. Fishman, 1995, Pneumocystis carinii and parasitic infections in transplantation, Infectious Disease Clinics of North America, 9, 1005, 10.1016/S0891-5520(20)30713-3 · doi:10.1016/s0891-5520(20)30713-3
  124. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, 2009, KDIGO clinical practice guideline for the care of kidney transplant recipients. Chapter 13.2: Cytomegalovirus, American Journal of Transplantation, 9, S46
  125. Keenan, 1991, Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation, Transplantation, 51, 433, 10.1097/00007890-199102000-00032 · doi:10.1097/00007890-199102000-00032
  126. Michaels, 2000, Infections in lung and heart-lung transplant recipients, 363
  127. Rubin, 2000, Infection in solid organ transplant: an introduction, 246
  128. Valantine, 1999, Role of CMV in transplant coronary artery disease and survival after heart transplantation, Transplant Infectious Disease, 1 Suppl 1, 25
  129. Hodson, 2005, Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003774 · doi:10.1002/14651858.cd003774

Cited by

See all 268

Metadata

Authors
Hodson, E. M., Ladhani, M., Webster, A. C., Strippoli, G. F., & Craig, J. C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2013-02-28
Issue
2
Pages
CD003774-CD003774
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2147425701
Cited by
268
References
80
FWCI
14.49
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. https://app.cochat.ai/papers/10.1002/14651858.cd003774.pub4
The paper
Hodson, E. M., Ladhani, M., Webster, A. C., Strippoli, G. F., & Craig, J. C. (2013). Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003774.pub4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.